ReNeuron Group plc Jefferies 2019 Global Healthcare Conference
31 May 2019 - 4:00PM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
31 May 2019
31 May 2019 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Jefferies 2019 Global Healthcare Conference
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is pleased to announce that
the Company's management team will be participating in 1-on-1
meetings at the Jefferies 2019 Global Healthcare Conference on
Tuesday 4 June 2019 in New York City.
For further information on the conference, please visit the
following link: Jefferies 2019 Global Healthcare Conference
ENDS
Contacts:
ReNeuron +44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US Media/Investor Relations) +1 212 600 1902 or
Claudia Styslinger, David Rosen email
claudia@argotpartners.com
Stifel Nicolaus Europe Limited (NOMAD and
Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison +44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor +44 (0) 20 7496 3000
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop
'off-the-shelf' stem cell treatments, without the need for
immunosuppressive drugs. The Company's lead clinical-stage
candidates are in development for the blindness-causing disease,
retinitis pigmentosa and for disability as a result of stroke.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that would
otherwise be unable to reach their site of action. ReNeuron's
shares are traded on the London AIM market under the symbol RENE.L.
Further information on ReNeuron and its products can be found at
www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKDDPPBKKNPN
(END) Dow Jones Newswires
May 31, 2019 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024